GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
NovaBay Pharmaceuticals Inc. (NBY) [hlAlert]

Rating:
Buy NBY
down 38.09 %

NovaBay Pharmaceuticals Inc. (NBY) rated Buy with price target $0.23 by Maxim Group

Posted on: Monday,  Dec 14, 2015  2:25 PM ET by Maxim Group

Maxim Group rated Buy NovaBay Pharmaceuticals Inc. (AMEX: NBY) on 12/14/2015. Previously Maxim Group rated Buy NovaBay Pharmaceuticals Inc. (AMEX: NBY) on
04/30/2015., when the stock price was $0.63. Since then, NovaBay Pharmaceuticals Inc. has lost 38.10% as of 08/27/2015's recent price of $0.39.
If you would have followed the previous Maxim Group's recommendation on NBY, you would have lost 38.09% of your investment in 119 days.

NovaBay Pharmaceuticals, Inc. (NovaBay) is a clinical-stage biopharmaceutical company developing synthetic anti-infective product candidates to treat and prevent a range of infections, without developing resistance, in hospital and non-hospital environments. The Company?s Aganocide compounds are synthetic forms of N-chlorinated antimicrobial molecules, which are effective and acting anti-infective molecules produced by white blood cells when defending the body against invading pathogens. In preclinical testing, its Aganocide compounds have demonstrated the ability to destroy bacteria, against which they have been tested. On March 25, 2009, the Company announced that it had entered into an agreement with Galderma S.A. to develop and commercialize its Aganocide compounds.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/14/2015 2:25 PM Buy
None
0.23
as of 8/27/2015
1 Week down  -4.87 %
1 Month down  -40.90 %
3 Months down  -35.00 %
1 YTD down  -38.09 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
4/30/2015 9:25 AM Buy
None
0.63 2.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy